Stock Watch: The Pandemic – Where Generics Failed To Reign
Big Generic Companies Seem To Have Suffered More Than Big Pharma
Executive Summary
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.